Latest & greatest articles for furosemide

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on furosemide or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on furosemide and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for furosemide

1. Simpson's Paradox: Meta-Analysis Comparing Torsemide Versus Furosemide in Patients With Heart Failure. (Abstract)

Simpson's Paradox: Meta-Analysis Comparing Torsemide Versus Furosemide in Patients With Heart Failure. 32098657 2020 03 31 1879-1913 125 8 2020 Apr 15 The American journal of cardiology Am. J. Cardiol. Simpson's Paradox: Meta-Analysis Comparing Torsemide Versus Furosemide in Patients With Heart Failure. 1285 S0002-9149(20)30075-8 10.1016/j.amjcard.2020.01.031 Baduashvili Amiran A Division of Hospital Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA. eng Letter 2020 02

2020 The American journal of cardiology

2. Continuous versus intermittent administration of furosemide in acute decompensated heart failure: a systematic review and meta-analysis. (Abstract)

Continuous versus intermittent administration of furosemide in acute decompensated heart failure: a systematic review and meta-analysis. Diuretic therapy is important in critically ill patients because fluid overload impairs organ function and increases mortality. Compared to intermittent administration, continuous infusion of loop diuretics is theoretically superior in terms of diuresis and electrolyte balance. However, the available evidence is susceptible to carryover diuretic effects (...) analyzed 12 parallel-group randomized controlled trials involving 923 patients. Compared with intermittent administration, continuous infusion of furosemide was not associated with an improvement in all-cause mortality (risk ratio 1.19; 95% confidence interval [CI], 0.65 to 2.16), length of hospital stay (weighted mean difference [WMD] - 0.88 days; 95% CI, - 2.76 to 1.01), or 24-h urine output (WMD 489.17 mL; 95% CI, - 183.18 to 1161.51), but was significantly associated with a greater body weight

2020 Heart Failure Reviews

3. Comparing torsemide versus furosemide in patients with heart failure: A meta-analysis. (Abstract)

Comparing torsemide versus furosemide in patients with heart failure: A meta-analysis. To compare the efficacy and safety of torsemide versus furosemide in patients with heart failure (HF).Medline, Cochrane Library, Web of Science, and Google Scholar database searches for relevant articles from 1946 to May 2018 were performed with the use of the key words torsemide and furosemide.Studies were included if they met the following criteria: (1) cohort studies or randomized controlled trials (...) of adult patients 18 years of age or older who received oral torsemide or furosemide for HF with reduced or preserved ejection fraction; and (2) studies that reported mortality rate, rehospitalization rate for HF or cardiovascular disease (CVD), or New York Heart Association (NYHA) functional class changes.Efficacy outcomes were mortality from any cause, rehospitalization for HF, rehospitalization for CVD, and NYHA functional class improvement. Safety outcome included hypokalemia.In the 5 included

2020 Journal of the American Pharmacists Association : JAPhA

4. Correction to: Association between furosemide in premature infants and sensorineural hearing loss and nephrocalcinosis: a systematic review. (Full text)

Correction to: Association between furosemide in premature infants and sensorineural hearing loss and nephrocalcinosis: a systematic review. [This corrects the article DOI: 10.1186/s40748-018-0092-2.].

2020 Maternal health, neonatology and perinatology PubMed abstract

5. Impact of furosemide on mortality and the requirement for renal replacement therapy in acute kidney injury: a systematic review and meta-analysis of randomised trials. (Full text)

Impact of furosemide on mortality and the requirement for renal replacement therapy in acute kidney injury: a systematic review and meta-analysis of randomised trials. To examine the impact of furosemide on mortality and the need for renal replacement therapy (RRT) in adult patients with acute kidney injury (AKI) based on current evidence.PubMed (Medline) and Embase were searched from 1998 to October 2018.We retrieved data from randomised controlled trials comparing prevention/treatment (...) with furosemide at any stage of AKI with alternative treatment/standard of care/placebo. The outcome was short-term mortality and the requirement for RRT, when applicable.Two reviewers independently extracted appropriate data. PRISMA guidelines were followed for data preparation and reporting.We identified 20 relevant studies (2608 patients: 1330 in the treatment arm and 1278 in the control arm). Heterogeneity between studies was deemed acceptable, and the publication bias was low. Furosemide had neither

2020 Annals of intensive care PubMed abstract

6. Effects of post-operative furosemide in adult surgical patients: A systematic review and meta-analysis of randomised clinical trials. (Full text)

Effects of post-operative furosemide in adult surgical patients: A systematic review and meta-analysis of randomised clinical trials. Acute kidney injury (AKI) is associated with increased morbidity and mortality and may present as oliguria in the post-operative phase. Diuretics, including furosemide, are commonly used in post-operative patients. Accordingly, we aimed to assess the balance between benefits and harms of furosemide post-operatively in adult surgical patients.We conducted (...) a systematic review with meta-analysis according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statements, the Cochrane Handbook and the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology. We included randomised clinical trials (RCTs) comparing post-operative treatment with furosemide vs no furosemide in adult surgical patients. Risk ratios (RR) with 95% confidence intervals (CI) were estimated by conventional meta-analysis and trial

2020 Acta Anaesthesiologica Scandinavica PubMed abstract

7. Torasemide versus furosemide in treatment of heart failure: A systematic review and meta-analysis of randomized controlled trials. (Abstract)

Torasemide versus furosemide in treatment of heart failure: A systematic review and meta-analysis of randomized controlled trials. Diuretics are a cornerstone in treatment of heart failure (HF). Torasemide is a loop diuretic with a potential advantage over other diuretics. We aim to meta-analyse and compare the effect of torasemide with furosemide in HF patients.A comprehensive literature search using 12 databases including PubMed, Scopus, and Web of Science was performed. All randomized (...) controlled trials (RCTs) comparing furosemide and torasemide in HF patients were included and meta-analysed. We assessed the risk of bias using Cochrane Collaboration's tool. The protocol was registered in PROSPERO (CRD42016046112).Eighteen RCTs with 1598 patients were included. There was a significant difference between torasemide 20 mg and furosemide 40 mg in increasing the urine volume (standard difference of the mean (SDM) [95% confidence interval] = -0.78 [-1.52 to -0.053], P = .036). Torasemide 10

2020 Journal of evaluation in clinical practice

8. Continuous Infusion Versus Intermittent Boluses of Furosemide in Acute Heart Failure: A Systematic Review and Meta-Analysis. (Abstract)

Continuous Infusion Versus Intermittent Boluses of Furosemide in Acute Heart Failure: A Systematic Review and Meta-Analysis. Acute heart failure is a common cause of hospital admission. This study aims to compare continuous infusion and intermittent boluses of furosemide in treating acute heart failure.Electronic searches were performed on PubMed, Medline, Scopus, and EMBASE. English articles comparing intermittent boluses and continuous infusion of furosemide in treating acute heart failure (...) patients (371 with intermittent boluses and 364 with continuous infusion). Mean daily urine output (P < .001) and weight loss (P = .04) were significantly higher in the continuous infusion group. Other variables were not significantly different between the two groups. TSA showed that current evidence is sufficient to draw the above conclusions about mean daily urine output, but more studies were required to compare the 2 regimens in terms of weight loss.Choice of furosemide regime in acute heart

2019 Journal of cardiac failure

9. Meta-Analysis Comparing Torsemide Versus Furosemide in Patients With Heart Failure (Full text)

Meta-Analysis Comparing Torsemide Versus Furosemide in Patients With Heart Failure Although torsemide's oral bioavailability and half-life theoretically render it a more efficient diuretic than furosemide, the clinical outcomes of torsemide compared with furosemide remain unclear. We performed a systematic review and meta-analysis, including all published studies that compared torsemide and furosemide use in heart failure patients from January 1996 through August 2019. Nineteen studies (9 (...) randomized control trials [RCTs] and 10 observational studies) with a total of 19,280 patients were included. During a mean follow-up duration of 15 months, torsemide was associated with a numerically lower risk of hospitalization due to heart failure (10.6% vs 18.4%; odds ratio [OR] 0.72, 95% confidence interval [CI] [0.51, 1.03], p = 0.07, I2 = 18%; number needed to treat [NNT] = 23) compared with furosemide. Torsemide was associated with statistically significant more improvement in functional status

2019 EvidenceUpdates PubMed abstract

10. Torsemide versus furosemide and intermediate-term outcomes in patients with heart failure: an updated meta-analysis. (Abstract)

Torsemide versus furosemide and intermediate-term outcomes in patients with heart failure: an updated meta-analysis. Loop diuretics have become a mainstay of chronic heart failure management. Furosemide and torsemide are the two most common loop diuretics; nevertheless, there is inconsistent evidence regarding the optimal choice of loop diuretic with respect to clinical outcomes.Medline and Cochrane Databases were systemically reviewed for randomized and observational studies comparing patients (...) with chronic heart failure on oral torsemide versus oral furosemide and their association with intermediate-term outcomes (5-12 months) through May 2018. Odds ratios with corresponding 95% confidence intervals (CIs) were used for outcomes. A random effect model was used to account for heterogeneity among studies. Heterogeneity was assessed with the Higgins I-square statistic.A total of 8127 patients were included in the analysis from a total of 14 studies (10 randomized, four observational); 5729 patients

2019 Journal of cardiovascular medicine (Hagerstown, Md.)

11. Torsemide versus furosemide in heart failure patients: A meta-analysis of randomized controlled trials. (Abstract)

Torsemide versus furosemide in heart failure patients: A meta-analysis of randomized controlled trials. 30177487 2019 04 11 2019 04 11 1879-0828 57 2018 11 European journal of internal medicine Eur. J. Intern. Med. Torsemide versus furosemide in heart failure patients: A meta-analysis of randomized controlled trials. e38-e40 S0953-6205(18)30359-5 10.1016/j.ejim.2018.08.015 Shah Priyank P Department of Internal Medicine, Medical College of Georgia-Southwest Clinical Campus, Albany, Georgia (...) Comparative Study Letter Meta-Analysis 2018 09 01 Netherlands Eur J Intern Med 9003220 0953-6205 7LXU5N7ZO5 Furosemide W31X2H97FB Torsemide IM Furosemide therapeutic use Heart Failure drug therapy mortality Humans Patient Readmission statistics & numerical data Randomized Controlled Trials as Topic Time Factors Torsemide therapeutic use Treatment Outcome Cost-saving Furosemide Heart failure readmissions Torsemide 2018 08 19 2018 08 27 2018 9 5 6 0 2019 4 12 6 0 2018 9 5 6 0 ppublish 30177487 S0953-6205(18

2019 European journal of internal medicine

12. Efficacy of furosemide for treatment of liver cirrhosis: A systematic review protocol of randomized controlled trial. (Full text)

Efficacy of furosemide for treatment of liver cirrhosis: A systematic review protocol of randomized controlled trial. Previous clinical studies have reported that furosemide can be used to treat liver cirrhosis (LC) effectively. However, no study systematically explored this issue. This systematic review aims to investigate the efficacy and safety of furosemide for treatment of LC.This study will be conducted through searching the following literature sources from their inception to February 28 (...) , 2019 without any language limitations: PUBMED, EMBASE, PsycINFO, Web of Science, Scopus, OpenGrey, Cochrane Library, Cumulative Index to Nursing and Allied Health Literature, Allied and Complementary Medicine Database, and Chinese Biomedical Literature Database. In addition, reference lists of relevant reviews and websites of clinical trial registry will also be searched. Only randomized controlled trials of furosemide for treatment of LC will be included in this study. Two reviewers

2019 Medicine PubMed abstract

13. Association between furosemide in premature infants and sensorineural hearing loss and nephrocalcinosis: a systematic review (Full text)

Association between furosemide in premature infants and sensorineural hearing loss and nephrocalcinosis: a systematic review Furosemide is a potent loop diuretic commonly and variably used by neonatologists to improve oxygenation and lung compliance in premature infants. There are several safety concerns with use of furosemide in premature infants, specifically the risk of sensorineural hearing loss (SNHL), and nephrocalcinosis/nephrolithiasis (NC/NL). We conducted a systematic review of all (...) trials and observational studies examining the association between these outcomes with exposure to furosemide in premature infants. We searched MEDLINE, EMBASE, CINAHL, and clinicaltrials.gov. We included studies reporting either SNHL or NC/NL in premature infants (< 37 weeks completed gestational age) who received at least one dose of enteral or intravenous furosemide. Thirty-two studies met full inclusion criteria for the review, including 12 studies examining SNHL and 20 studies examining NC/NL

2018 Maternal health, neonatology and perinatology PubMed abstract

14. Furosemide

Furosemide Top results for furosemide - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for furosemide The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you

2018 Trip Latest and Greatest

15. Association between Furosemide Exposure and Patent Ductus Arteriosus in Hospitalized Infants of Very Low Birth Weight (Full text)

Association between Furosemide Exposure and Patent Ductus Arteriosus in Hospitalized Infants of Very Low Birth Weight To evaluate the association between furosemide exposure and patent ductus arteriosus (PDA) in a large, contemporary cohort of hospitalized infants with very low birth weight (VLBW).Using the Pediatrix Medical Group Clinical Data Warehouse, we identified all inborn infants of VLBW <37 weeks of gestation discharged from the neonatal intensive care unit after the first postnatal (...) to mechanical ventilation and inotropes. Furosemide was prescribed to 4055 (9%) infants. On multivariable regression, exposure to furosemide was associated with decreased odds of PDA treatment (OR 0.72; 95% CI 0.65-0.79). Increasing percentage of days with furosemide exposure was not associated with PDA treatment (OR 1.01; 95% CI 0.97-1.06).Furosemide exposure was not associated with increased odds of PDA treatment in hospitalized infants of VLBW. Further studies are needed to characterize the efficacy

2018 EvidenceUpdates PubMed abstract

16. Continuous Infusion versus Intermittent Bolus Injection of Furosemide in Critically Ill Patients: A Systematic Review and Meta-analysis. (Abstract)

Continuous Infusion versus Intermittent Bolus Injection of Furosemide in Critically Ill Patients: A Systematic Review and Meta-analysis. Fluid overload is a common phenomenon seen in intensive care units (ICUs). However, there is no general consensus on whether continuous or bolus furosemide is safer or more effective in these hemodynamically unstable ICU patients. The aim of this meta-analysis was to examine the clinical outcomes of continuous versus bolus furosemide in a critically ill (...) population in ICUs.MEDLINE, EMBASE, PubMed, and the Cochrane Database of Systematic reviews were searched from their inception until June 2017.All randomized controlled trials, observational studies, and case-control studies were included. Case reports, case series, nonsystematic reviews, and studies that involved children were excluded.Nine studies (n = 464) were eligible in the data synthesis. Both continuous and bolus furosemide resulted in no difference in all-cause mortality (7 studies; n = 396; I2

2018 Journal of cardiothoracic and vascular anesthesia

18. Intermittent furosemide administration in patients with or at risk for acute kidney injury: Meta-analysis of randomized trials. (Full text)

Intermittent furosemide administration in patients with or at risk for acute kidney injury: Meta-analysis of randomized trials. Furosemide is the most common loop diuretic used worldwide. The off-label administration of furosemide bolus(es) for the prevention or to reverse acute kidney injury (AKI) is widespread but not supported by available evidence. We conducted a meta-analysis of randomized trials (RCTs) to investigate whether bolus furosemide to prevent or treat AKI is detrimental (...) on patients' survival.Electronic databases were searched through October 2017 for RCTs comparing bolus furosemide administration versus any comparator in patients with or at risk for AKI. The primary endpoint was all-cause longest follow-up mortality. Secondary endpoints included new or worsening AKI, receipt of renal replacement therapy, length of hospital stay, and peak serum creatinine after randomization.A total of 28 studies randomizing 3,228 patients were included in the analysis. We found

2018 PLoS ONE Controlled trial quality: predicted high PubMed abstract

19. Temporal bone histopathology of furosemide ototoxicity (Full text)

Temporal bone histopathology of furosemide ototoxicity To describe the human temporal bone pathology in two patients who incurred furosemide induced ototoxicity.1) A 46-year-old woman in acute liver and renal failure treated with high doses of furosemide for anasarca who developed a rapidly progressive severe-to-profound asymmetric sensorineural hearing loss. 2) A 65-year-old woman with undifferentiated small cell carcinoma of the lung who received intravenous furosemide 1 day prior to death (...) for pulmonary edema.Removal of temporal bones, histologic processing, and light microscopy of temporal bones.Temporal bone histopathology and correlation with clinical and audiometric data.All three temporal bones demonstrated edema and cystic changes in the stria vascularis. In the first case the furosemide exposure was associated with hearing loss and the pathological changes were more extensive including cystic changes in the Hensen's cells, collapse of Reissner's membrane and the tectorial membrane

2017 Laryngoscope investigative otolaryngology PubMed abstract

20. Peritoneal Dialysis vs Furosemide for Prevention of Fluid Overload in Infants After Cardiac Surgery: A Randomized Clinical Trial

Peritoneal Dialysis vs Furosemide for Prevention of Fluid Overload in Infants After Cardiac Surgery: A Randomized Clinical Trial PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2017 PedsCCM Evidence-Based Journal Club